Literature DB >> 29427105

Spinocerebellar Ataxia Type 17 (SCA17).

Yasuko Toyoshima1, Hitoshi Takahashi2.   

Abstract

In 1999, a polyglutamine expansion was identified in the transcription factor TATA-binding protein (TBP) in a patient with ataxia with negative family history. Subsequently, CAG/CAA repeat expansions in the TBP gene were identified in families with spinocerebellar ataxia (SCA), establishing this repeat expansion as the underlying mutation in SCA type 17 (SCA17). There are several characteristic differences between SCA17 and other polyglutamine diseases. First, SCA17 shows a complex and variable clinical phenotype, in some cases overlapping that of Huntington's disease. Second, compared to the other SCA subtypes caused by expanded trinucleotide repeats, anticipation in SCA17 kindreds is rare because of the characteristic structure of the TBP gene. And thirdly, SCA17 patients often have diagnostic problems that may arise from non-penetrance. Because the gap between normal and abnormal repeat numbers is very narrow, it is difficult to determine a cutoff value for pathologic CAG repeat number in SCA17. Herein, we review the clinical, genetic and pathologic features of SCA17.

Entities:  

Keywords:  Chorea; Dementia; Dystonia; Huntington’s disease-like; Spinocerebellar ataxia

Mesh:

Substances:

Year:  2018        PMID: 29427105     DOI: 10.1007/978-3-319-71779-1_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

Review 1.  Molecular Mechanisms and Therapeutics for SCA17.

Authors:  Qiong Liu; Yongcheng Pan; Xiao-Jiang Li; Shihua Li
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

2.  Complexity of the Genetics and Clinical Presentation of Spinocerebellar Ataxia 17.

Authors:  Suran Nethisinghe; Wei N Lim; Heather Ging; Anna Zeitlberger; Rosella Abeti; Sally Pemble; Mary G Sweeney; Robyn Labrum; Charisse Cervera; Henry Houlden; Elisabeth Rosser; Patricia Limousin; Angus Kennedy; Michael P Lunn; Kailash P Bhatia; Nicholas W Wood; John Hardy; James M Polke; Liana Veneziano; Alfredo Brusco; Mary B Davis; Paola Giunti
Journal:  Front Cell Neurosci       Date:  2018-11-23       Impact factor: 5.505

Review 3.  A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases.

Authors:  Sean L Johnson; Wei-Ling Tsou; Matthew V Prifti; Autumn L Harris; Sokol V Todi
Journal:  Front Mol Neurosci       Date:  2022-09-14       Impact factor: 6.261

Review 4.  Juvenile Huntington's Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data.

Authors:  Karolina Świtońska-Kurkowska; Bart Krist; Joanna Delimata; Maciej Figiel
Journal:  Front Cell Dev Biol       Date:  2021-07-01

Review 5.  Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Authors:  Patrik Fazio; Martin Paucar; Per Svenningsson; Andrea Varrone
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-05       Impact factor: 5.081

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.